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INTRODUCTION 
Hypertension or high blood pressure is a chronic 
medical condition in which the blood pressure in the 
arteries is elevated. It is classified as either primary 
(essential) or secondary. About 90-95 % of cases are 
termed "primary hypertension", which refers to high 
blood pressure for which no medical cause can be found 
the remaining 5-10 % of cases (Secondary hypertension) 
are caused by another conditions that affect the kidneys, 
arteries, heart, or endocrine system. Blood pressure is 
classified based on two types of measurements, the 
systolic and diastolic blood pressures expressed as a ratio 
such as '120 over 80' (120/80) mmHg. Systolic blood 
pressure is the blood pressure in vessels during a 
heartbeat. Diastolic blood pressure is the pressure 
between heartbeats. 
Aliskiren is a (ALS),(2S, 4S, 5S, 7S)- N-(2-carbamoyl-
2-methylpropyl)-5-amino-4- hydroxy-2,7-diisopropyl-8-
[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide 
hemifumarate (Figure-1).The first oral direct rennin 
inhibitor approved for clinical use, exhibits a novel and 
advantageous pharmacokinetic and pharmacodynamic 
profile for the long-term treatment of hypertension. 
Aliskiren blocks the renin system at its rate-limiting step 
by directly inhibiting the catalytic activity of renin, 
thereby reducing generation of angiotensin I and 
angiotensin II(1). 
it is a highly potent and selective inhibitor of human 
renin in vitro, and in vivo; once-daily oral doses of 
Aliskiren inhibit renin and lower blood pressure in 
sodium-depleted marmosets and hypertensive human 
patients. Aliskiren represents the first in a novel class of 
renin inhibitors with the potential for treatment of 
hypertension and related cardiovascular diseases. 
Aliskiren administered both orally or intravenously. 
Aliskiren is also available as combination therapy with  
Amlodipine and Hydrochlorothiazide. 
 
Figure 1; Chemical structure of Aliskiren 
Felodipine is a long-acting 1,4-dihydropyridine calcium 
channel blocker . Felodipine is a dihydropyridine deriva-
tive that is chemically described as ethyl methyl (RS) 4-
(2, 3-dichlorophenyl) - 1, 4-dihydro-2, 6-
dimethylpyridine-3, 5-dicarboxylate (Figure-2). It acts 
primarily on vascular smooth muscle cells by stabilizing 
voltage-gated L-type calcium channels in their inactive 
conformation. By inhibiting the influx of calcium in 
smooth muscle cells, Felodipine prevents calcium-
dependent myocyte contraction and vasoconstric-
tion(2),,(3),. Felodipine is the most potent CCB in use and 
is unique in that it exhibits fluorescent activity. In addi-
tion to binding to L-type calcium channels, Felodipine 
binds to a number of calcium-binding proteins, exhibits 
competitive antagonism of the mineralcorticoid receptor, 
inhibits the activity of calmodulin-dependent cyclic nuc-
leotide phosphodiesterase, and blocks calcium influx 
through voltage-gated T-type calcium channels. Felodi-
pine is used to treat mild to moderate essential hyperten-
sion(4),(5),(6). 
ABSTRACT 
A simple, fast, specific and accurate reverse-phase high performance liquid chromatography (RP-HPLC) method has been 
developed and subsequently validated for simultaneous estimation of Aliskiren (ALN) and Felodipine (FLD) from their dosage 
forms. Agilent 1200 infinity LC equipped with UV-Visible with EZChrom Elite compact version 3.3.2 SP2 software was used. 
Chromatographic separation was achieved isocratically on a Hypersil BDS C8 column (150×4.6 mm, 5 μ particle size) using a 
mobile phase, Water (adjusted to pH 3.0 with 10%v/v ortho-phosphoric acid) , Acetonitrile and Methanol in the ratio of  
20:30:50 v/v/v and UV detection was carried out at 254 nm for both the drugs ALN and FLD. The retention time for ALS and 
FLD was found to be 4.26 and 2.96 min respectively, and recoveries were found between 98 and 102%.  The method was 
found linear over the range of 150-450 µg mL-1 for ALS and  5-15 µg mL-1  for FLD. The method has been successfully 
applied to assess the assay of solid dosage formulations. 
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Figure 2: Chemical structure of Felodipine 
MATERIAL AND METHODS: 
Experimental Chromatographic conditions 
The analysis of the drug was carried out on a Agilent 
1200 infinity LC system equipped with EZChrom Elite 
compact version 3.3.2 SP2 software using Hypersil BDS 
C8 column (150×4.6 mm, 5 μ particle size) at ambient 
temperature.  A degassed mixture of Water (adjusted to 
pH 3.0 with 10% ortho-phosphoric acid) , Acetonitrile 
and Methanol in the ratio of  20:30:50 v/v/v was used as 
mobile phase and detection was carried out at 254 nm. 
Chemicals and Solvents 
The Aliskiren (ALS) and Felodipine (FLD) Working 
standards were kindly gifted by Morepen Laboratories 
Ltd, New Delhi and AUM Research Laboratories, 
Ahmedabad-India. HPLC grade methanol and 
Acetonitrile were purchased from FINAR Limited. 
Ortho-phosphoric acid of AR Grade were obtained from 
S.D. Fine Chemicals Ltd. 
Preparation of mobile phase and diluent 
Mobile phase: 
500 ml of Milli-Q water was adjusted to pH 3.0 using 
10%v/v ortho-phosphoric acid and filtered through 
0.45filter under vacuum. 200 ml of water (adjusted to pH 
3.0 with 10%v/v ortho-phosphoric acid) was mixed with 
300 ml of Acetonitrile and 500 ml of Methanol and the 
resulting mixture was degassed in an ultrasonic water 
bath for 15 minutes. 
Diluent: 
A mixture of Water and Methanol in ration of 50:50v/v 
used as diluent. 
Procedure 
A mixture of water (adjusted to pH 3.0 with 1% ortho-
phosphoric acid) and Acetonitrile and Methanol in the 
ratio of 20:30:50 v/v was found to be the most suitable 
mobile phase for  separation of Aliskiren and Felodipine. 
The solvent mixture was sonicated before use. It was 
pumped through the column at a flow rate of 1.0 ml/min. 
The column was maintained at ambient temperature.  
The column was equilibrated by pumping the mobile 
phase through the column for at least 30 min prior to the 
injection of the drug solution. The detection of the drug 
was monitored at wavelength 254 nm. The injection 
volume was set 10µl and sample run time was set at 6 
min. Under these optimized chromatographic conditions 
the retention time obtained for the drugs ALS and FLD 
were 4.26 and 2.95 min respectively. System suitability 
data are summarized in Table 1. A typical chromatogram 
showing the separation of the drugs is given in Figure-3.
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Figure 3: Chromatogram depicting for Fumaric acid, Felodipine and Aliskiren peak 
Linearity study: 
Stock solution preparation: 
About 150 mg of ALS and 5 mg of FLD was weighed 
accurately, transferred into a individual 50 ml volumetric 
flask and dissolved in 5 ml of methanol added and 
sonicated to dissolve for 5 minutes. Make up the volume 
with diluent (i.e. mixture of Water and Methanol in ratio 
of 50:50 v/v). 
Mix Standard preparation: 
Mix standard preparation of both the drugs were 
prepared  by dilution of the standard stock preparation 
with diluent to obtain the concentration range of  300 µg 
mL-1  and 10 µg mL-1 for ALS and FLD respectively. 
Linearity solution preparation: 
Linearity solution was prepared by dilution of standard 
stock solution with diluent to obtained linearity 
concentration rage of 150 - 450 µg mL-1  and 5-15 µg 
mL-1  for ALS and FLD respectively.10 µl of Five  
injections of mixed standard solution preparation and 
single injection of linearity solution was injected into the 
column at a flow rate of 1.0 ml/min and the 
corresponding chromatograms were obtained. From 
these chromatograms, the average area under the peak of 
each preparation was computed. The Linearity graph 
constructed by plotting concentration of the drug against 
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peak area was found to be linear in the concentration 
range of 150-450 µg mL-1 for ALS and 5-15 µg mL-1  for 
FLD. The regression equations of this curves was 
computed. The relevant data are furnished in Table 1 & 2 
and figure 4 & 5.  
 
 
Figure 4: Linearity Graph for Aliskiren Peak. 
 
 
Figure 5: Linearity Graph for Felodipine Peak. 
Specificity of the proposed method: 
Identification solution reparation: 
Identification solution for ALS: 
Identification solution was prepared by dilution of the 
standard stock preparation with diluent to obtain the 
concentration at about  300 µg mL-1  for ALS. 
Identification solution for FLD: 
Identification solution was prepared by dilution of the 
standard stock preparation with diluent to obtain the 
concentration at about 10 µg mL-1  for FLD. 
Identification of Fumaric acid peak: 
Identification solution was prepared by using Fumaric 
acid reagent and diluent. The solution of about 30 µg 
mL-1 of Fumaric acid solution was used and injected as 
per method. 
Placebo preparation: 
Identical mix placebo was prepared for ALS and FLD 
formulations and injected for placebo interference study. 
Above prepared solution were analyzed by using 
proposed method. Obtained chromatogram were 
evaluated for Interference of the Fumaric acid and 
placebo. The relevant data are furnished in Table 1. 
Accuracy of the proposed method: 
The accuracy of the HPLC method was assessed by 
analyzing solutions of ALS and FLD at 50, 100 and 
150% concentration level.by the proposed method. The 
accuracy of the method was established based on the 
summary given in Table 1 
 
Table 1: Chromatographic Data 
 ALS peak FLD peak 
Theoretical plate >2000 >5000 
Asymmetry 1.15 1.80 
Resolution from previous peak > 4.5 >9.0 
Linearity range  (µg/ml) 150-450 µg mL-1   5-15 µg mL-1   
Correlation coefficient 0.999 0.999 
Limit of Quantification 3 µg mL-1   0.1 µg mL-1   
%RSD (n=5) 0.34 1.02 
Recovery 98-102% 98-102% 
Specificity Specific Specific 
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Table 2: Linearity Study for ALS and FLD 
ALS peak FLD peak 
Concentration in µg mL
-1
   Peak Area Concentration in µg mL
-1   Peak Area 
150 925019 5 810028 
225 1411699 7.5 1219612 
300 1868121 10 1633368 
375 2310896 12.5 1988990 
450 2787431 15 2427710 
 
DISCUSSION 
In the proposed method, the retention time of ALS and 
FLD was found to be 4.26 and 2.95 minute. 
Quantification was linear in the concentration range of 
150- 450μg/ml for ALS and 5-15μg/ml for FLD. The 
regression equation of the linearity plot of concentration 
of ALS over its peak area was found to be y = 46240x + 
47342(r2=0.999) for ALS and y = 40047x + 41451 
(r2=0.999) for FLD, where X is the concentration of ALS 
and FLD (μg/ml) and Y is the corresponding peak area. 
The number of theoretical plates calculated was 2000 for 
ALS and 3000 for FLD, which indicates efficient 
performance of the column. The  limit of quantification 
for ALS were found to be 3.0μg/ml and  for FLD were 
found to be 0.1 μg/ml, which indicate the sensitivity of 
the method. The recovery study indicates that the 
proposed method is highly accurate. No interfering peaks 
were found in the chromatogram of the formulation 
within the run time indicating that excipients used in  
formulations did not interfere with the estimation of the 
drug by the proposed HPLC method. 
CONCLUSION 
The developed HPLC method was validated and the 
statistical validation was performed with the simplicity, 
and ease of operation ensures that the validated method 
can successfully used for routine analysis of Aliskiren 
hemifumarate and Felodipine in bulk and formulation. It 
is of practical utility because all the molecules are 
available in individual formulations or will be available 
in its future combinations. The application of this method 
in routine analysis can be justified since easy sample 
preparation steps are involved with simple reagents and 
solvents were used experimentally. The method can be 
employed in quality control of pharmaceuticals 
containing Aliskiren and Felodipine to reduce analytical 
time. 
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